BPC-157

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

BPC-157 is not an FDA-approved drug and has no IND-authorized clinical use outside registered trials. It may not legally be sold for human consumption. Removal from the Category 2 bulk drug substances list (effective ~April 22, 2026) means the specific compounding prohibition has been lifted, but compounding access still requires a final FDA rulemaking following PCAC review scheduled for July 23–24, 2026 (docket FDA-2025-N-6895). Until that process concludes, the practical legal pathway for compounded BPC-157 remains unsettled.

Transparent blend · bci-1.0 · never paid-placement

Primary name

BPC-157

Origin

Derived from a partial sequence of human gastric juice protein BPC. BPC-157 (also designated PL-14736) is a synthetic 15-amino-acid peptide that does not occur freely in nature but is modeled on a region of the endogenous gastric body protection compound. It carries CAS 137525-51-0 and has been studied exclusively in preclinical settings, with two registered clinical trials (NCT02637284 Phase 1 pharmacokinetics; NCT07437547 Phase 2 hamstring injury, recruiting as of 2026).

Registry IDs

PubChem CID

9941957

CAS

137525-51-0

InChIKey

HEEWEZGQMLZMFE-RKGINYAYSA-N

DrugBank

DB11882

ChEMBL

CHEMBL4297358

Molecular formula

C62H98N16O22

Molar mass

1419.5 g/mol

Monoisotopic

1418.70415882 Da

InChIKey

HEEWEZGQMLZMFE-RKGINYAYSA-N

Appearance

White to off-white lyophilized powder

Solubility

Soluble in water and dilute acetic acid (0.1% acetic acid commonly used for reco…

Sequence not available in current seed.

Stability: Stable as lyophilized powder under recommended cold-chain conditions. Reconstituted solution stability is not formally characterized in peer-reviewed literature

Vial sizes

5 mg · 10 mg

Purity grades

≥98% (HPLC)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• BPC-157 has been shown in rodent and cell-culture studies to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) and activate downstream Akt–eNOS signaling, promoting endothelial nitric oxide production and new vessel formation
• The peptide also engages the focal adhesion kinase (FAK)–paxillin pathway, facilitating endothelial cell migration during angiogenesis
• Additional preclinical data indicate modulation of nitric oxide synthesis more broadly, with context-dependent protective effects against cytotoxic NO excess while preserving physiological NO-mediated functions
• These converging angiogenic and cytoprotective pathways are proposed to underlie observations of accelerated wound closure, tendon reattachment, and gastrointestinal mucosal recovery in animal injury models

Pharmacokinetics (ADME)

Half-life

Approximately 5–15 minutes (IV; rat and dog models); subcutaneous half-life not formally characterized

Clearance

Rapid hepatic proteolysis to constituent amino acids; route of elimination not fully characterized in published literature

PK–PD note: A marked PK–PD disconnect has been noted: despite rapid plasma clearance (minutes), downstream signaling effects on angiogenesis and collagen synthesis in animal models persist for days to weeks. No v…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Vasireddi et al. 2025 systematic review (HSS J / SAGE) — 544 screened; 36 included = 35 preclinical + 1 human — the anchor for 'almost entirely animal evidence.'
• STAT: big claims and scant evidence (Feb 2026)
• Undark: secretive scientist / COI investigation (May 2026) — Details Sikiric conflicts of interest (patents, sponsor ownership) undisclosed on papers.
• MDPI 2025 literature & patent review

2 registered trials — 1 currently recruiting.

Phase 1
NCT02637284
PCO-02 - Safety and Pharmacokinetics Trial

UNKNOWN

Phase 2
NCT07437547
BPC 157 for Acute Hamstring Muscle Strain Repair

RECRUITING

Summary (literature)

Formal preclinical toxicology studies (cited in ScienceDirect 2020 evaluation) reported no compound-related findings in single-dose and repeat-dose toxicity studies in rodents and dogs, including no genotoxicity or embryo-fetal toxicity. A transient, dose-dependent decrease in se…

WADA status

Prohibited at all times under WADA 2026 Prohibited List: S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)…

Dominant research route: Preclinical efficacy work is dominated by intragastric/oral (drinking water) and injected IP/IM in rats and mice. The ONLY route with formal published pharmacokinetics is IV and IM (rats and beagle dogs). Subcutaneous is the most common community-reported human route but has no published PK.

Some preclinical use; the most commonly community-reported human route, but no dedicated SC pharmacokinetic study.

Bioavailability: No published SC pharmacokinetic/bioavailability data. SC absorption in humans is unquantified.

The route most often described in community reports; absorption and kinetics are not established in the literature. No human dosing implied.

Formally characterized in the single published PK study (Sprague-Dawley rats + beagle dogs), incl. repeated 7-day dosing. Animal-only.

Bioavailability: Absolute bioavailability ≈14–19% in rats and ≈45–51% in dogs; rat Tmax ~3 min; elimination half-life <30 min. Preclinical, species-dependent.

One of only two routes with published pharmacokinetics — both in animals.

Formally characterized in the single published PK study (rats + dogs); reference route for half-life. Animal-only.

Bioavailability: 100% bioavailable by definition. Elimination half-life ~15.2 min (rat) and ~5.27 min (dog), <30 min overall; linear PK; rapidly metabolized to peptide fragments/amino acids, excreted via urine + bile.

Defines the short plasma half-life (minutes). Reviews note biological effects appear to outlast the peptide's brief plasma presence. Preclinical only.

Heavily used systemic route in the rat/mouse efficacy literature (organ-injury, GI, CNS models). Animal-only; not a human route.

Bioavailability: No dedicated IP pharmacokinetic characterization; used as a dosing route in efficacy studies rather than PK studies.

A laboratory-animal administration route, cited only to describe how preclinical work was conducted.

Studied in animals mainly via drinking water / intragastric dosing for GI and organ-protection endpoints. No published human oral PK.

Bioavailability: Stable in human gastric juice >24 h, so it survives the stomach — but gastric survival ≠ systemic absorption, and oral bioavailability has never been quantified in any species. Strongest oral evidence is LOCAL/GI-tract.

Whether meaningful amounts reach systemic circulation orally is unproven. No human oral efficacy or dosing implied.

Minimal formal study (limited local animal work, e.g. rat rhinitis). Widely sold as vendor nasal sprays → predominantly community-reported. No human intranasal trial.

Bioavailability: No intranasal pharmacokinetic/bioavailability data. The 'nose-to-brain' rationale is extrapolated from other molecules and not demonstrated for BPC-157.

Largely a marketed / anecdotal route; CNS-delivery claims are unverified for this peptide.

Studied in animal wound models: BPC-157 cream on skin/burn wounds improved LOCAL healing. Not a systemic route.

Bioavailability: Used for local action at the wound; systemic absorption through skin not quantified. Applied alone (no carrier), unlike growth factors.

Local wound-healing evidence in animals (ERK1/2-associated). No systemic-delivery or human-benefit claim.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $5.20 · median $6.50 · p75 $9.70 · 11 researched vendors

Legit, COA-backed band: $5.00–$8.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$49

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Reputable research-market vendors cluster ~96.8–99.95% HPLC purity (Finnrick aggregate, 666 BPC-157 samples / 98 vendors). Grey/lower-tier vendors fall well below — an independent 10-sample investigation (MZ Biolabs, Jan 2026) found tier-4 BPC-157 at ~71.3% purity with detectable lead and endotoxin.

Independent labs cited for this compound

No specific product recall of a BPC-157 product was found (2023–2026). As an unapproved drug sold outside the regulated supply chain, FDA action takes the form of warning letters, import detention, raids and criminal cases rather than Class I/II/III recalls. Reported honestly as an empty recall result, not invented.

Buyer red-flag checklist

• No batch-specific COA provided on request (community rule: assume underdosed / contaminated).
• COA report/task ID does not resolve in the lab's public database (fabricated or edited certificate).
• Vial lot number doesn't match the lot on the COA (a single 'showcase' COA reused across batches).
• Purity-only COA with no LC-MS identity (can't rule out wrong compound / substitution).
• No endotoxin (LAL) or sterility data for a product implied for injection.
• Price far below the market median for the mg size (consistent with underfilled/off-spec product).
• Human-dosing / benefit marketing on a 'research use only' site — the pattern drawing FDA letters.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Mislabeling/underdosing is a documented tail risk, not universal. Finnrick reports advertised mg fill diverging by up to ±71% vs label at the 95th percentile; the MZ Biolabs investigation failed 3 of 10 peptides (all tier-3/4), including one wrong-compound substitution. A widely-repeated '43% failed purity' figure could not be confirmed against a primary lab publication and is treated as unverified.

• The peptide-relevant FDA import controls are Import Alert 66-41 (detention-without-physical-examination of unapproved new drugs, which covers peptides marketed as research chemicals, incl. BPC-157) and, for GLP-1 APIs, the Import Alert 66-80 'Green List' (issued 19 Sep 2025). An RUO label is not an import exemption — CBP judges actual intended use.66-41 (unapproved new drugs) + 66-80 (GLP-1 Green List)
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in- and out-of-competition) on the WADA 2026 Prohibited List under S0 (Non-Approved Substances). No approved human therapeutic use, so no Therapeutic Use Exemption pathway. USADA and DoD OPSS warn athletes and service members. (An 'S2' characterization circulates in vendor material but is not officially enumerated by anti-doping authorities — S0 is the load-bearing category.)

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Survivorship / positivity bias — dramatic recovery stories over-shared
• SEO / AI-generated 'Reddit review' vendor blogs pollute any automated tone read
• Affiliate / astroturfing incentive on 'best vendor' content
• Negativity bias in bad-experience threads
• Placebo / concurrent-substance confounding inherent to anecdotes
• Influencer amplification skews framing positive vs the thin human evidence

Manually researched from reddit, youtube, bluesky— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Synthetic 15-amino-acid gastric pentadecapeptide studied in animal models for tissue repair, angiogenesis, and GI protection. Approximately 218 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research use only; not approved; removed from FDA Category 2 compounding restriction list April 2026, pending PCAC review. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet